Aprepitant-13C2,d2 (Major)
| Product Name |
Aprepitant-13C2,d2 (Major)
|
| Product Code |
DA-A280-20
|
| Chemical name |
Aprepitant-13C2,d2 (Major)
|
| Synonyms |
5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one-13C2,d2; Emend-13C2,d2; MK-0869-13C2,d2;
|
| Impurity |
NA
|
| CAS Number |
1217676-37-3
|
| Alternate CAS # |
NA
|
| Molecular form |
C2113C2H19D2F7N4O3
|
| Appearance |
Off-White Solid
|
| Melting Point |
NA
|
| Mol. Weight |
538.42
|
| Storage |
2-8°C Refrigerator
|
| Solubility |
NA
|
| Stability |
NA
|
| Category |
chiral standards,heterocycles,pharmaceutical standards,intermediates,fine chemicals,stable isotopes
|
| Boiling Point |
NA
|
| Applications |
This product is deuterated at the 1 position and on the ajacent methyl. The 1 position is the benylic position of the bis(trifluoromethyl) phenyl. This compound has a mixture of 1 to 4 deuterium atoms, there is no detectable unlabeled material. Aprepitant is a structurally novel substance P neurokinin 1 (NK1) receptor antagonist. In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1.
|
| Dangerous Goods Info |
NA
|
| References |
NA
|
| Extra Notes |
NA
|
| Documents (MSDS) |
No Data Available
|
| Keywords |
NA |
